Blog

The clinical significance of tumor heterogeneity

  Traditionally, oncologists believed that solid-cancer tumors were largely homogeneous – that their molecular makeup was the same throughout the body—and treated their patients accordingly. We now know that tumors are far more complex. Not only are they densely heterogeneous1, and vary significantly both within and between primary and metastatic sites, they also change over […]

Read More

Largest ever study of non-small cell lung cancer patient cell-free circulating tumor DNA adds to growing evidence of Guardant360’s utility in guiding treatment decisions

VIENNA, Dec. 5, 2016 – Guardant Health reported the results of the largest ever genomic study of advanced non-small cell lung cancer (NSCLC) patient cell-free circulating tumor DNA (ctDNA) at the 17th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (IASLC). “It is clear from this retrospective […]

Read More

Introducing the enhanced Guardant360

  Guardant360, the gold standard in comprehensive liquid biopsy, helps oncologists maximize targeted treatment options for their advanced cancer patients. Ever since we pioneered the field of comprehensive liquid biopsy in 2014, we have continued to innovate with a singular focus on transforming cancer care. Blood-based cancer DNA testing is our main focus. It’s what […]

Read More

Liquid biopsies, a critical tool for the Cancer Moonshot

In his final State of the Union, President Obama announced the Cancer Moonshot, an ambitious national effort to accelerate cancer research. Critics said it was mission impossible. At Guardant Health, we believe that no single entity can deliver on the goals of the Cancer Moonshot, and it will take a coordinated effort to bend cancer […]

Read More

Guardant Health expands distribution of Guardant360, its breakthrough genomic cancer test, in the Middle East

Redwood City, Calif. and Dubai – September 19, 2016 – Guardant360®, the leading comprehensive liquid biopsy, will be available to more oncologists and their cancer patients in the Middle East through a distribution agreement between Guardant Health and IPS Genomix, the companies announced. “We believe the great promise of Guardant360 is its ability to democratize […]

Read More

Guardant Health and Oncotest-Teva announce exclusive distribution and marketing partnership for Guardant360 in Israel

REDWOOD CITY, Calif., June 27, 2016 – Guardant Health, the leader in comprehensive liquid biopsy, announced a distribution and marketing partnership with Oncotest-Teva, [a subsidiary of Teva Pharmaceutical Industries Ltd. in Israel]. The partnership will make Guardant360®, Guardant Health’s groundbreaking, non-invasive genomic sequencing test for patients with advanced cancer, widely available to oncologists and patients […]

Read More

Guardant Health, Pangaea Biotech, the Dr. Rosell Oncology Institute and MedSIR Announce a Strategic Collaboration to Study Liquid Biopsy in Spain

REDWOOD CITY, CALIF., and BARCELONA, May 19, 2016 — Guardant Health, Pangaea Biotech, the Dr. Rosell Oncology Institute (IOR) and MedSIR announced a strategic collaboration to study liquid biopsy from cancer patients in Spain. “Guardant360 has already helped thousands of patients avoid the costs, complications and delays of invasive biopsy procedures,” said Helmy Eltoukhy, Guardant […]

Read More

Guardant360® Now Available to Military Service Members at San Antonio Military Medical Center

REDWOOD CITY, Calif., April 22, 2016 – Guardant Health® announced that oncologists at San Antonio Military Medical Center, one of the U.S. military’s premier medical facilities, can now order the breakthrough liquid biopsy Guardant360 to help guide therapy selection for patients fighting advanced cancers, and to avoid further invasive biopsies. “We’re honored our technology can […]

Read More

Guardant Health® partners with Sanomics to distribute Guardant360® in Hong Kong and Macau

REDWOOD CITY, Calif., and HONG KONG, March 17, 2016 — Oncologists in Hong Kong and Macau can now order Guardant Health’s groundbreaking Guardant360 liquid biopsy for patients with advanced solid tumors, the companies announced. The partnership between Guardant Health and Sanomics expands Guardant Health’s distribution outside the United States, where nearly 2,000 oncologists are ordering […]

Read More

Guardant360 Stories: Susan

I was like most people when I was diagnosed with cancer in July 2012 – surprised, shocked and a bit of a deer in the headlights. “NOW, what do I do?” I asked myself. I have a cancer that is difficult to treat: triple negative breast cancer (TNBC), which means my cancer does not grow […]

Read More